Why NeuroBo Pharmaceuticals Shares Are Up Over 50%

NeuroBo Pharmaceuticals Inc NRBO shares are trading higher by 56.44%. Strength may be due to short interest in the stock and social media interest.

What Else?

NeuroBo Pharmaceuticals shares also saw marked strength last week after the company announced Dong-A has licensed its global exclusive development rights of DA-1241 for type 2 diabetes and non-alcoholic fatty hepatitis and DA-1726 for obesity and non-alcoholic fatty hepatitis to NeuroBo.

The company also began trading on a 1-for-30 reverse split basis September 13th.

See Also: So Does Elon Musk's Tesla Or Lucid Make The Cooler-Looking Electric Vehicle?

According to data from Benzinga Pro, NeuroBo Pharmaceuticals has a 52-week high of $123.90 and a 52-week low of $7.40.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: MoversTrading Ideaswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!